Pharmacokinetics and brain distribution studies of perphenazine-loaded solid lipid nanoparticles

References

• Radaic A , Martins-de-Souza D. The state of the art of nanopsychiatry for schizophrenia diagnostics and treatment. Nanomed Nanotechnol Biol Med. 2020; 28:102222.
   PubMed Web of Science ®Google Scholar
• Tandon R , Gaebel W , Barch DM , et al. Definition and description of schizophrenia in the DSM-5. Schizophr Res. 2013;150:3–10.
   PubMed Web of Science ®Google Scholar
• Laursen TM , Nordentoft M , Mortensen PB. Excess early mortality in schizophrenia. Annu Rev Clin Psychol. 2014;10:425–448.
   PubMed Web of Science ®Google Scholar
• Bloom DE , Cafiero E , Jané-Llopis E , et al. The global economic burden of noncommunicable diseases. Program on the Global Demography of Aging. 2012.
   Google Scholar
• Lin C-H , Chen C-H , Lin Z-C , et al. Recent advances in oral delivery of drugs and bioactive natural products using solid lipid nanoparticles as the carriers. J Food Drug Anal. 2017;25:219–234.
   PubMed Web of Science ®Google Scholar
• Baboota S , Mustafa AG , Sahni JK , et al. Mechanistic approach for the development of ultrafine oil-water emulsions using monoglyceride and blends of medium and long chain triglycerides: enhancement of the solubility and bioavailability of perphenazine. J Excip Food Chem. 2016;4:1099.
   Google Scholar
• Hartung B , Sampson S , Leucht S. Perphenazine for schizophrenia. Cochrane Database Syst Rev. 2015:CD003443.
   PubMed Web of Science ®Google Scholar
• Sun Y , Kang C , Liu F , et al. Delivery of antipsychotics with nanoparticles. Drug Dev Res. 2016;77:393–399.
   PubMed Web of Science ®Google Scholar
• Turunen E , Mannila J , Laitinen R , et al. Fast-dissolving sublingual solid dispersion and cyclodextrin complex increase the absorption of perphenazine in rabbits. J Pharm Pharmacol. 2011;63:19–25.
   PubMed Web of Science ®Google Scholar
• Dimitrijevic I , Pantic I. Application of nanoparticles in psychophysiology and psychiatry research. Rev Adv Mater Sci. 2014;83–88.
   Google Scholar
• Salunkhe SS , Bhatia NM , Kawade VS , et al. Development of lipid based nanoparticulate drug delivery systems and drug carrier complexes for delivery to brain. J App Pharm Sci. 2015;5:110–129.
   Google Scholar
• Meise U , Kurz M , Fleischhacker WW. Antipsychotic maintenance treatment of schizophrenia patients: is there a consensus? Schizophr Bull. 1994;20:215–225.
   PubMed Web of Science ®Google Scholar
• Müller RH , Mäder K , Gohla S. Solid lipid nanoparticles (SLN) for controlled drug delivery – a review of the state of the art. Eur J Pharm Biopharm. 2000;50:161–177.
   PubMed Web of Science ®Google Scholar
• Luo YFan , Chen DWei , Ren L , et al. Solid lipid nanoparticles for enhancing vinpocetine’s oral bioavailability. J Control Release. 2006;114:53–59.
   PubMed Web of Science ®Google Scholar
• Mehnert W , Mäder K. Solid lipid nanoparticles: production, characterization and applications. Adv Drug Delivery Rev. 2012;64:83–101.
   Web of Science ®Google Scholar
• Lavelle E , Sharif S , Thomas N , et al. The importance of gastrointestinal uptake of particles in the design of oral delivery systems. Adv Drug Delivery Rev. 1995;18:5–22.
   Web of Science ®Google Scholar
• Yang S , Zhu J , Lu Y , et al. Body distribution of camptothecin solid lipid nanoparticles after oral administration. Pharm Res. 1999;16:751–757.
   PubMed Web of Science ®Google Scholar
• Martins SM , Sarmento B , Nunes C , et al. Brain targeting effect of camptothecin-loaded solid lipid nanoparticles in rat after intravenous administration. Eur J Pharm Biopharm. 2013;85:488–502.
   PubMed Web of Science ®Google Scholar
• Patel M , Souto EB , Singh KK. Advances in brain drug targeting and delivery: limitations and challenges of solid lipid nanoparticles. Expert Opin Drug Deliv. 2013;10:889–905.
   PubMed Web of Science ®Google Scholar
• Kaur IP , Bhandari R , Bhandari S , et al. Potential of solid lipid nanoparticles in brain targeting. J Controlled Release. 2008;127:97–109.
   PubMed Web of Science ®Google Scholar
• Fond G , Macgregor A , Miot S. Nanopsychiatry-the potential role of nanotechnologies in the future of psychiatry: a systematic review. Eur Neuropsychopharmacol. 2013;23:1067–1071.
   PubMed Web of Science ®Google Scholar
• Natarajan J , Baskaran M , Humtsoe LC , et al. Enhanced brain targeting efficacy of Olanzapine through solid lipid nanoparticles. Artif Cells Nanomed Biotechnol. 2017;45:364–371.
   PubMed Web of Science ®Google Scholar
• Nikandish N , Hosseinzadeh L , Azandaryani AH , et al. The role of nanoparticle in brain permeability: an in-vitro BBB model. Iran J Pharm Res. 2016;15:403–413.
   PubMed Web of Science ®Google Scholar
• Joseph E , Saha RN. Investigations on pharmacokinetics and biodistribution of polymeric and solid lipid nanoparticulate systems of atypical antipsychotic drug: effect of material used and surface modification. Drug Dev Ind Pharm. 2017;43:678–686.
   PubMed Web of Science ®Google Scholar
• Kurd M , Sadegh Malvajerd S , Rezaee S , et al. Oral delivery of indinavir using mPEG-PCL nanoparticles: preparation, optimization, cellular uptake, transport and pharmacokinetic evaluation. Artif Cells Nanomed Biotechnol. 2019;47:2123–2133.
   PubMed Web of Science ®Google Scholar
• Müller RH , Rühl D , Runge S , et al. Cytotoxicity of solid lipid nanoparticles as a function of the lipid matrix and the surfactant. Pharm Res. 1997;14:458–462.
   PubMed Web of Science ®Google Scholar
• Pandita D , Ahuja A , Lather V , et al. Development of lipid-based nanoparticles for enhancing the oral bioavailability of paclitaxel. Aaps Pharmscitech. 2011;12:712–722.
   PubMed Web of Science ®Google Scholar
• Nooli M , Chella N , Kulhari H , et al. Solid lipid nanoparticles as vesicles for oral delivery of olmesartan medoxomil: formulation, optimization and in vivo evaluation. Drug Dev Ind Pharm. 2017;43:611–617.
   PubMed Web of Science ®Google Scholar
• Hansen LB , Larsen N-E. Plasma concentrations of perphenazine and its sulphoxide metabolite during continuous oral treatment. Psychopharmacology (Berl). 1977;53:127–130.
   PubMed Web of Science ®Google Scholar
• Naseri N , Valizadeh H , Zakeri-Milani P. Solid lipid nanoparticles and nanostructured lipid carriers: structure, preparation and application. Adv Pharm Bull. 2015;5:305–313.
   PubMed Web of Science ®Google Scholar
• Bhalekar MR , Madgulkar AR , Desale PS , et al. Formulation of piperine solid lipid nanoparticles (SLN) for treatment of rheumatoid arthritis. Drug Dev Ind Pharm. 2017;43:1003–1010.
   PubMed Web of Science ®Google Scholar
• Nasiri F , Faghfouri L , Hamidi M. Preparation, optimization and in-vitro characterization of α-tocopherol-loaded solid lipid nanoparticles (SLNs). Drug Dev Ind Pharm. 2020;46:142–159.
   Web of Science ®Google Scholar
• Yasir M , Sara UVS. Solid lipid nanoparticles for nose to brain delivery of haloperidol: in vitro drug release and pharmacokinetics evaluation. Acta Pharm Sin B. 2014;4:454–463.
   PubMed Web of Science ®Google Scholar
• Laitinen R , Suihko E , Bjorkqvist M , et al. Perphenazine solid dispersions for orally fast-disintegrating tablets: physical stability and formulation. Drug Dev Ind Pharm. 2010;36:601–613.
   PubMed Web of Science ®Google Scholar
• Dudhipala N , Janga KY. Lipid nanoparticles of zaleplon for improved oral delivery by Box-Behnken design: optimization, in vitro and in vivo evaluation. Drug Dev Ind Pharm. 2017;43:1205–1214.
   PubMed Web of Science ®Google Scholar
• Zhang Y , Huo M , Zhou J , et al. PKSolver: An add-in program for pharmacokinetic and pharmacodynamic data analysis in Microsoft Excel. Comput Methods Programs Biomed. 2010;99:306–314.
   PubMed Web of Science ®Google Scholar
• Freitas C , Müller RH. Effect of light and temperature on zeta potential and physical stability in solid lipid nanoparticle (SLN™) dispersions. Int J Pharm. 1998;168:221–229.
   Web of Science ®Google Scholar
• Jepson MA , Clark M , Foster N , et al. Targeting to intestinal M cells. J Anat. 1996;189:507.
   PubMed Web of Science ®Google Scholar
• Dwivedi P , Khatik R , Khandelwal K , et al. Pharmacokinetics study of arteether loaded solid lipid nanoparticles: an improved oral bioavailability in rats. Int J Pharm. 2014;466:321–327.
   PubMed Web of Science ®Google Scholar
• Manjunath K , Venkateswarlu V. Pharmacokinetics, tissue distribution and bioavailability of nitrendipine solid lipid nanoparticles after intravenous and intraduodenal administration. J Drug Target. 2006;14:632–645.
   PubMed Web of Science ®Google Scholar
• Chen L-T , Weiss L. The role of the sinus wall in the passage of erythrocytes through the spleen. Blood. 1973;41:529–537.
   PubMed Web of Science ®Google Scholar
• Harde H , Das M , Jain S. Solid lipid nanoparticles: an oral bioavailability enhancer vehicle. Expert Opin Drug Deliv. 2011;8:1407–1424.
   PubMed Web of Science ®Google Scholar
• Jose S , Anju S , Cinu T , et al. In vivo pharmacokinetics and biodistribution of resveratrol-loaded solid lipid nanoparticles for brain delivery. Int J Pharm. 2014;474:6–13.
   PubMed Web of Science ®Google Scholar
• de Mendoza AE-H , Préat V , Mollinedo F , et al. In vitro and in vivo efficacy of edelfosine-loaded lipid nanoparticles against glioma. J Controlled Release. 2011;156:421–426.
   PubMed Web of Science ®Google Scholar
• Kakkar V , Mishra AK , Chuttani K , et al. Proof of concept studies to confirm the delivery of curcumin loaded solid lipid nanoparticles (C-SLNs) to brain. Int J Pharm. 2013;448:354–359.
   PubMed Web of Science ®Google Scholar
• Girotra P , Singh SK. Multivariate optimization of rizatriptan benzoate-loaded solid lipid nanoparticles for brain targeting and migraine management. AAPS PharmSciTech. 2017;18:517–528.
   PubMed Web of Science ®Google Scholar